Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
GENERALI SPA UNSP ADR EACH REPR 0.50 ORD stock (ARZGY) sits at $23.52, up 0.86% today. The business is worth $70.29B in the market, good for #320 of 2132 on our coverage list.
Over the past 52 weeks it has traded between $18.61 and $26.49, so it sits 11.2% below the top of that range. Holders are ahead 28.4% over twelve months, but down 3.1% across the last three months.
Price is below the 50-day average ($25.33) but above the 200-day ($22.15); RSI is 33, and the last 30 sessions moved at roughly 23% annualized volatility.
Buyers are paying 13.7 times trailing earnings.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 2 factors below, ranked against the 2132 U.S. stocks BeStock covers.
Higher trailing yield than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
ARZGY is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -6.7% | Bearish |
| Price vs 50-day average | -7.1% | Bearish |
| Price vs 200-day average | +6.2% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 32.6 | Bearish |
| MACD (12,26,9) | -0.50 | Bearish |
| Bollinger band position | 9% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 5, 2026 9:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 2,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$23.52 is the latest print for ARZGY, a move of +0.86% against yesterday's close of $23.32. Today's low and high so far: $23.18 and $23.52.
Equity value comes to $70.29B at the current price. By that measure it is number 320 of the 2132 names in our coverage.
Buyers pay 13.7 times the last twelve months of profit (EPS $1.72).
The year's floor is $18.61 and the ceiling $26.49. Shares are 11.2% away from that ceiling.
It does. Payouts over the past twelve months work out to a 4.07% yield.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on ARZGY.